The Cigna Group (CI)
Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) Surpasses Q2 Earnings and Revenue Estimates
Cigna (CI) came out with quarterly earnings of $7.2 per share, beating the Zacks Consensus Estimate of $7.14 per share. This compares to earnings of $6.72 per share a year ago.
Cigna Profits Hit $1.5 Billion Despite Higher Costs
The Cigna Group reported a second quarter profit of $1.5 billion as its Evernorth health service business performs well and despite rising costs in its employer health benefits business.
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10 Undervalued Dividend Growth Stocks: July 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Why Cigna (CI) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes?
Cigna Group: Is The Value Real Or Are Investors Just Stuck In Neutral?
The Cigna Group's risk/reward is balanced after a rebound; I rate it Hold—worth keeping if owned, but not a compelling buy right now. The Evernorth pharmacy benefits arm drives growth, but regulatory risk and insurance challenges keep me cautious until a clearer catalyst emerges. Cigna's fundamentals are solid—growing earnings, strong cash flow, shareholder returns—but the stock is fairly valued versus peers, not a bargain.
Cigna: Price Pullback Is A Great Opportunity
Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it attractive for total return investors. CI's robust earnings growth is fueled by its Evernorth and Healthcare segments, with strong results and promising exposure to the booming GLP-1 drug market. Management targets 10-14% annual EPS growth, supported by aggressive share buybacks and a safe, growing dividend nearly double the S&P 500 yield.
Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment
CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.
4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy
Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Cigna: Valuation Discount To Historical And Sector Averages Persists
Cigna has transformed into a diversified healthcare platform, focusing on high-margin corporate insurance and pharmacy services while divesting non-core assets. Despite margin pressures, Cigna's service-driven model delivers strong revenue growth, stable cash flows, and resilient EPS, supported by robust buybacks and dividend increases. My DCF analysis shows Cigna is undervalued, trading at a deep discount to sector peers, with an 11%+ upside and limited downside risk even in conservative scenarios.
